BiotechTube
vTv Therapeutics

vTv Therapeutics

VTVTPhase 3
High Point, United StatesFounded 2015vtvtherapeutics.com

vTv Therapeutics is a clinical-stage company dedicated to improving the lives of people with diabetes through innovative oral therapies. Its primary mission is to develop cadisegliatin, which aims to become the first FDA-approved oral adjunctive treatment to insulin for Type 1 Diabetes, addressing the persistent challenge of hypoglycemia and glycemic control. The company is publicly traded on NASDAQ (VTVT) and is advancing its late-stage pipeline with a focus on liver-selective glucokinase activation. Its strategic direction is centered on successfully completing the Phase 3 trial and navigating the regulatory pathway for its lead candidate.

Market Cap
$141.8M
+109.3% period
Pipeline
14
3 in Phase 3
Patents
—
Publications
—

VTVT · Stock Price

USD 36.00+18.80 (+109.30%)

Historical price data

AI Company Overview

vTv Therapeutics is a clinical-stage company dedicated to improving the lives of people with diabetes through innovative oral therapies. Its primary mission is to develop cadisegliatin, which aims to become the first FDA-approved oral adjunctive treatment to insulin for Type 1 Diabetes, addressing the persistent challenge of hypoglycemia and glycemic control. The company is publicly traded on NASDAQ (VTVT) and is advancing its late-stage pipeline with a focus on liver-selective glucokinase activation. Its strategic direction is centered on successfully completing the Phase 3 trial and navigating the regulatory pathway for its lead candidate.

DiabetesChronic Diseases

Technology Platform

Focus on liver-selective glucokinase activation for glucose regulation, utilizing oral small molecule drug candidates designed to modulate the body's natural glucose sensing and storage mechanisms in the liver.

Pipeline

14
14 drugs in pipeline3 in Phase 3
DrugIndicationStageWatch
Azeliragon + PlaceboAlzheimer's DiseasePhase 3
Azeliragon 5mgAlzheimer's DiseasePhase 3
Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + PlaceboDiabetes Mellitus, Type 1Phase 3
TTP054 + PlaceboType 2 Diabetes MellitusPhase 2
Azeliragon + PlaceboAlzheimer DiseasePhase 2

Opportunities

The primary opportunity is addressing the massive unmet need in Type 1 Diabetes as the first FDA-approved oral adjunctive therapy to insulin.
Success could lead to expansion into other indications, such as specific subsets of Type 2 Diabetes, and establish the company's liver-selective GKA platform as a validated approach for metabolic diseases.

Risk Factors

The company faces extreme binary risk centered on the Phase 3 trial outcome for its sole lead asset.
Additional risks include potential regulatory hurdles, future dilution from necessary capital raises, and eventual commercialization challenges as a small biotech in a competitive diabetes market.

Competitive Landscape

vTv's main competitors are SGLT2 inhibitors used off-label (with DKA risk) and injectable pramlintide. Its key differentiation is the novel, liver-selective mechanism of cadisegliatin, which aims to lower glucose without increasing DKA risk and offers the convenience of oral administration, potentially providing a safer and more effective adjunctive option for T1D management.